Pipeline
A New Kind of Antibody Therapy
Sorriso is building a pipeline of novel oral antibodies to address unmet need in various immune-mediated diseases.
The programs
SOR101 Program: Oral Anti-TNFa
SOR101 represents an opportunity to manage ICI mediated colitis (IMC) with an oral, gut-restricted treatment approach.
SOR102 Program: Oral anti-TNF⍺/anti-IL-23
SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression.
SOR104 Program: anti-IL-7R⍺ (IL-7/TSLP)
SOR104 is an anti-IL-7Ra Vorabody that blocks IL-7 and TSLP mediated signalling.